139 related articles for article (PubMed ID: 31296640)
1. Conjunctival lymphoma.
Li JJ; Chen W; Sadeghi N
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31296640
[No Abstract] [Full Text] [Related]
2. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
3. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
4. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
5. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
6. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine reactivates latent Epstein-Barr virus.
Fernandez SG; Miranda JJ
Leuk Lymphoma; 2016 May; 57(5):1208-10. PubMed ID: 26371746
[No Abstract] [Full Text] [Related]
8. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
9. [Conjunctival lymphosarcoma].
Nicu C
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Ser Oftalmol; 1988; 32(3):211-6. PubMed ID: 2973636
[No Abstract] [Full Text] [Related]
10. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
[No Abstract] [Full Text] [Related]
11. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
Schmidt C; Fingerle-Rowson G; Boehme A; Brendel K; Fischer R; Gonnermann M; Höhler T; Kegel T; Kellermann L; Nusch A; Pönisch W; Wendtner C; Dreyling M
Leuk Lymphoma; 2015 Mar; 56(3):694-702. PubMed ID: 24937122
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.
Rice ML; Barreto JN; Thompson CA; Mara KC; Tosh PK; Limper AH
Cancer Med; 2021 Aug; 10(15):5120-5130. PubMed ID: 34155819
[TBL] [Abstract][Full Text] [Related]
13. [An immunohistochemical study of primary malignant lymphomas of orbital and adnexal regions].
Suenaga M; Shioya H; Kato K; Wakasa H
Nippon Ganka Gakkai Zasshi; 1988 Jun; 92(6):1057-62. PubMed ID: 3263761
[No Abstract] [Full Text] [Related]
14. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
15. [Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Du KX; Shen HR; Wang L; Liang JH; Wu JZ; Li Y; Xia Y; Yin H; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):333-336. PubMed ID: 37357004
[No Abstract] [Full Text] [Related]
16. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
17. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
[TBL] [Abstract][Full Text] [Related]
19. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
20. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
[No Abstract] [Full Text] [Related]
[Next] [New Search]